Glucose transporter 1 (GLUT-1) and GLUT-14 are of high prognostic value in gastric adenocarcinoma, a recent study published online ahead of print in the journal Annals of Surgical Oncology has shown.
For the study, researchers analyzed tumor sections that were removed during gastrectomy in 124 patients with gastric adenocarcinoma. Patients underwent surgery between 1996 and 2007. Researchers were looking for associations between GLUT-1, GLUT-14, and HIF1-alpha antibodies and patient survival.
Results showed that median survival in patients with GLUT-1 was 14 months (95% CI: 9.2, 18.8) and 55 months (95% CI: 25.8, 84.2; P=0.01) in patients that were GLUT-1-negative.
Continue Reading
Researchers also found that GLUT-14-positive patients had a worse prognosis compared with those that were GLUT-14-negative (P=0.004).
RELATED: Weekly Oraxol for Second-Line Treatment of Metastatic, Recurrent Gastric Cancer
When researchers adjusted for confounding factors in multivariate analysis, GLUT-1 and GLUT-14 continued to be independent factors for prognosis.
The findings suggest that further prospective studies are warranted to confirm these results in order to better identify patients with inferior prognosis.
Reference
